Skip to content
ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

Get the podcast

Robert Mayer Thierry Facon Ibrahim Yakoub-Agha Peter Paschka Robert Mayer of the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at

The Audio Journal of Oncology
Robert Mayer

Robert Mayer

Thierry Facon

Thierry Facon

 Ibrahim Yakoub-Agha

Ibrahim Yakoub-Agha

Peter Paschka

Peter Paschka

Robert Mayerof the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at the 2006 ASCO meeting.

– Older patients with multiple myeloma can benefit from adding thalidomide to their standard therapy of melphalan and prednisone; and the thalidomide regimen is also better than melphalan followed by autologous stem cell transplantation.Thierry Faconfrom the University of Lille told ASCO delegates about his group’s findings (Abstract 1)
– A decreased dose of thalidomide may be just as effective in multiple myeloma while having a better side effect profile – but should these results change practice?Ibrahim Yakoub-Aghafrom the University of Lille had the data at ASCO (Abstract 7520)
– Imatinib is still proving effective at treating chronic myeloid leukemia, even after more than 5 years of follow up.Robert Mayerdescribes the latest findings from the IRIS study
– In the “core-binding factor” subtype of acute myeloid leukemia, certain mutations in the KIT gene predict for a poor prognosis. This could help tailor therapy for this disease, according toPeter Paschkaof Ohio State University

Tags

hematologicleukemiamyelomatransplantationtrial

Next in ASCO 2006

All 15 interviews

Interview 10 of 15

ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

Dean Bajorin Robert Motzer Gary Hudes Marshall Posner Some major progress in kidney cancer and head and neck cancer was announced at the ASCO meeting in Atlanta, and the Audio Journal of Oncology has

4 June 2006

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Audio Journal of Oncology Volume 16 Number 8

Audio Journal of Oncology Volume 16 Number 8

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

15 Apr 2008